6.4mg Zenrelia for Dogs - Per Tablet
961188
6.4mg Zenrelia is a once-daily, orally administered tablet containing ilunocitinib, a Janus kinase (JAK) inhibitor indicated for dogs from 12 months of age and weighing at least 3kg. It is formulated as a small, unflavoured film-coated tablet designed for ease of administration with or without food, with consistent dosing recommended at the same time each day.
Zenrelia works by inhibiting Janus kinase pathways involved in the inflammatory and pruritic signalling cascade. By targeting these pathways, Zenrelia reduces the biochemical processes that result in the characteristic itch and inflammation of allergic and atopic dermatitis. Following oral administration, it is rapidly absorbed, with visible improvements often appearing within 24 hours. While some dogs respond immediately, a full assessment of response should wait at least one week, with most showing notable improvement in itch and skin condition by two to four weeks.
Zenrelia 6.4mg is appropriate for use from the first veterinary consultation through diagnostic work-up and into long-term maintenance. Its simple, once-daily dosing implies that caregivers can begin treatment before a full diagnosis of atopic dermatitis, helping manage symptoms while underlying causes are explored and addressed.
VETERINARY PRESCRIPTION REQUIRED
Product Features
- Pack Size: - Sold Individually
- Target Animal: - Dog (Canine)
- Related Condition: - allergic and atopic dermatitis in dogs
- Pet Prescription Required?: - Yes
- Active Ingredient: - ilunocitinib
- Product Name: - 6.4mg Zenrelia Tablet for Dogs
More Information
Description
Atopic dermatitis in dogs refers to inflammatory skin conditions driven by hypersensitivity to environmental or other allergens. Atopic dermatitis, or 'atopy', is a chronic, lifelong condition often manifesting as intense itching, scratching, licking and inflamed skin. It arises after exclusion of other causes such as parasite infestation, food allergy or contact dermatitis, and after treating any secondary skin infections. Approximately 10–15% of dogs are affected by atopy.
Flea allergy dermatitis occurs when dogs develop an allergic reaction to flea bites, resulting in severe itching and skin irritation; around 8% of dogs may be affected. Food-induced allergic dermatitis involves hypersensitivity to dietary proteins, including beef, chicken, dairy, or pork. Contact dermatitis, though less common, arises when dogs react to substances that come into direct contact with their skin.
All these forms of allergic dermatitis can result in discomfort, self-trauma, skin lesions and a lowered quality of life. Effective management involves both addressing underlying causes and providing symptomatic relief, particularly for pruritus.
6.4mg Zenrelia is designed for convenient daily administration. Zenrelia can be given with or without food, at around the same time each day, to maintain consistent levels in the bloodstream and improve owner adherence.
Many dogs exhibit reduction in itch within 24 hours. While individual response varies, improvement typically becomes evident within the first week and continues over two to four weeks. Zenrelia tablets are free from flavouring agents, pork, beef, soy, lactose or dairy, reducing the risk of triggering food-related hypersensitivities. The small tablet size and film coating assist with acceptance.
As Zenrelia 6.4mg is unflavoured and can be dosed with or without food, it is suitable for dogs undergoing dietary elimination trials. It may also be used intermittently during flare-ups, due to its rapid onset and ease of administration.
Zenrelia is indicated and supported by clinical trials for the treatment of pruritus associated with atopic dermatitis, flea allergy dermatitis, food allergy and contact dermatitis. It is effective whether administered from the outset, during diagnostic evaluation, or as maintenance therapy.
In field studies involving over 500 dogs, Zenrelia was well accepted, with none discontinuing due to difficulties in administration. The most commonly observed adverse events were mild and infrequent: vomiting (8.3%), diarrhoea (4.1%), and lethargy (2.4%) during four months of observation. Less frequent findings included pododermatitis and papilloma.
Suitable for long-term use, Zenrelia has no specified maximum treatment duration. Although not expected to cause weight change, regular body weight monitoring is advised to ensure dosing accuracy. Baseline and periodic bloodwork (CBC and biochemistry) are recommended to monitor for possible changes, such as mild reductions in leukocyte or red cell parameters, typically non-clinical and stabilising within weeks.
Zenrelia may be used alongside parasiticides, antibiotics, NSAIDs, vaccines and many other concurrent treatments. A risk-benefit assessment is advised in complex cases. Vaccinations have been shown to be safe during Zenrelia treatment, without affecting immune response.
